A. Gottschalk
Papers
1
Total Citations
2
H-Index
1
About
A. Gottschalk is a leading figure in radiation oncology, with a focused expertise in stereotactic body radiation therapy (SBRT) for prostate cancer. Their major contribution lies in pioneering hypofractionated SBRT boost techniques for intermediate- and high-risk prostate cancer, as demonstrated in their seminal 2013 prospective study. This work, which has garnered 2 citations, established critical benchmarks for delivering high-dose radiation in fewer, more intense fractions, improving treatment precision while reducing overall patient burden. Gottschalk’s research has directly influenced clinical protocols by demonstrating the safety and efficacy of this approach, offering a viable alternative to conventional fractionation. Their achievements include advancing the integration of SBRT into standard prostate cancer care, where their findings continue to guide dose escalation strategies and toxicity management. For students and researchers, Gottschalk’s work exemplifies how targeted, hypofractionated radiation can optimize oncologic outcomes, making them a key contributor to the evolution of modern, patient-centered radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1